Welcome to IDEA Collider with your host, Rick Ritacco. In this episode, we sit down with Jason Tardio, President and COO of Immunic, to discuss the rapidly evolving landscape of Multiple Sclerosis (MS) treatment. For 30 years, MS therapies have primarily focused on controlling inflammation and visible relapses. Jason argues it’s time to look deeper and address the ongoing neurodegeneration driving long-term disability, known as Progression Independent of Relapse Activity (PIRA).

We explore Immunic's investigational therapy, vidofludimus calcium, and its unique dual-mechanism approach: acting as a DHODH inhibitor for anti-inflammatory benefits while also activating the Nurr1 nuclear receptor to potentially provide direct neuroprotection. Jason shares insights from the EMPHASIS and CALIBER clinical trials, discusses why the industry needs safer immunomodulators rather than just broad immunosuppressants (especially as the MS population ages), and shares a fascinating biological link between MS remission during pregnancy and Nurr1 levels. Tune in to hear what the next 10 to 15 years hold for MS patients, including the ultimate goals of halting progression entirely and achieving remyelination.

Episode Timestamps

00:00:00 - Introduction: Meet Jason Tardio, President and COO of Immunic.

00:02:01 - The Evolution of MS Treatment: Transitioning from purely anti-inflammatory approaches to addressing underlying neurodegeneration.

00:04:29 - What is PIRA?: Understanding Progression Independent of Relapse Activity and why patients still accumulate disability.

00:10:30 - The Dual-Mechanism Approach: How vidofludimus calcium combines DHODH inhibition with Nurr1 activation.

00:13:33 - The Power of Nurr1: Exploring the target's role in neuronal survival and the fascinating biological link to pregnancy in MS patients.

00:18:14 - Clinical Validation: Analyzing data from the EMPHASIS (relapsing MS) and CALIBER (progressive MS) trials.

00:27:42 - Standing Out in a Crowded Market: Why safety, tolerability, and avoiding broad immunosuppression matter, especially for aging MS patients facing immunosenescence.

00:36:08 - The Next 10 Years: Moving towards halting progression, potential remyelination, and the need to reclassify MS beyond relapsing and progressive labels.

Keep up with Jason Tardio;

LinkedIn: https://www.linkedin.com/in/jason-tardio/

Keep up with Rick Ritacco:

LinkedIn: https://www.linkedin.com/in/rritacco/

Follow IDEA Pharma On;

Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to a special edition of IDEA Collider’s "Deep Medicine" series. In this episode, host Alex Gray sits down with Athina Metaxa, a consultant at IDEA Pharma and psychedelic research expert, to discuss the rapidly shifting landscape of psychedelic medicine. With substantial unmet needs in treatment-resistant depression (TRD) and PTSD, the field is at a critical inflection point marked by new FDA prioritizations and breakthrough clinical data.

Athina shares insights from her meta-analysis on psilocybin and discusses the unique methodological challenges facing the industry, such as blinding integrity and the influence of expectancy effects in clinical trials. We explore the debate over whether the "psychedelic experience" is necessary for therapeutic benefit and how biotechs are balancing regulatory-friendly trial designs with patient safety.

Finally, Athina looks toward the future of precision psychiatry, examining the role of biomarkers and the immense logistical challenges of scaling these intensive therapies within global healthcare systems.

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Athina Metaxa; LinkedIn:

https://www.linkedin.com/in/athina-marina-metaxa/

Follow IDEA Pharma On; Website:

https://www.ideapharma.com/

Listen to more fantastic podcast episodes:

https://ideacollider.simplecast.com/

Welcome to IDEA Collider with your host, Rick Ritacco.

In this episode, we sit down with Sue Wood, a senior expert at IDEA Pharma with a PhD from Oxford and decades of experience translating complex scientific concepts into relevant narratives. Sue discusses the unique challenges biotechs face with early positioning, explaining why teams often struggle with the paradox of having immediate scientific certainty about a molecule but immense clinical uncertainty about its future.

We explore how to simplify scientific messaging without "dumbing it down," and Sue shares three proven strategies: reappropriating non-pharma nomenclature, evolving familiar drug classes, and focusing on tangible clinical outcomes. Sue also highlights the importance of cross-functional alignment, noting that a team's conviction to execute a narrative often matters more than having absolute precision.

Tune in to hear her hilarious origin story involving the Boston Globe and oat bran donuts, and learn actionable advice on what biotechs should immediately remove from their websites.

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Sue Wood; LinkedIn: https://www.linkedin.com/in/susan-wood-266631244/

Follow IDEA Pharma On; Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

Welcome to IDEA Collider. In this episode, host Dr. Alex Gray, Chief Medical and Innovation Officer at IDEA Pharma, is joined by colleague Jacqueline Poot, President of Strategic Consulting and Analytics, to discuss the intricacies of pharmaceutical portfolio strategy.

This episode has accompanying slides that can be found on YouTube https://youtu.be/DKdy_MShWBA

They tackle the growing view that the pharmaceutical industry doesn't just have a science problem; it has an execution problem. Alex breaks down how human biases, such as confirmation bias and champion bias, can derail clinical development and lead to poor portfolio choices. They emphasize that stopping a failing project early is just as critical to an organization's overall success as advancing a good one.

The episode explores successful decision-making frameworks from top-performing companies, analyzing how AstraZeneca's 5Rs framework reversed late-stage failures and examining structured matrices such as Roche's RAVE, Amgen's RAVE, and Pfizer's DICE. Alex also highlights Eli Lilly's highly successful Chorus unit and their use of AI to drive objective resource allocation. Tune in to hear why relying solely on standard Probability of Technical Success (PTS) models or Risk-Adjusted NPV is flawed, how operational issues drive numerous Phase 3 failures, and the incremental but powerful role machine learning will play in the next generation of drug development.

Welcome to IDEA Collider. In this episode, host Alex Gray is joined by IDEA Pharma colleagues David Radwaner and Tom Brockbank to dissect the history, strategy, and future of immuno-oncology (IO). The trio explores how PD-1 and PD-L1 therapies revolutionized cancer treatment, acting as a brake on the immune system to offer unprecedented durability and long-term survival for patients.

They take a deep dive into the fascinating commercial and clinical race between Merck's Keytruda and BMS's Opdivo. Learn how Merck's strategic decisions—including smart statistical trial designs, targeted biomarker approaches in first-line non-small cell lung cancer, and tumor-agnostic labels like MSI-high—allowed Keytruda to secure market dominance. Finally, Alex, David, and Tom look ahead to the next ten years, discussing whether emerging players like AstraZeneca and China's Akeso / Summit will displace Keytruda, or if the future lies in combination therapies.

Episode Timestamps:

00:00:00 - Introduction: Meet David Radwaner, Tom Brockbank, and host Alex Gray.

00:01:45 - The Origins of IO: The Nobel Prize-winning discovery of PD-1 and CTLA-4 checkpoints.

00:03:55 - Why PD-1 / PD-L1 Won: The unique breadth of utility and unparalleled durability of long-term survival.

00:06:21 - Keytruda vs. Opdivo: How Merck's strategic trial design and smart statistical work outpaced BMS's early lead.

00:11:48 - The NSCLC Inflection Point: Why narrowing the patient population (PD-L1 - 50%) cemented Keytruda's foundation in first-line lung cancer.

00:14:20 - Tumor-Agnostic Success: Merck's bold move into MSI-high and broad biomarker-led strategies.

00:16:09 - Science or Luck? Analyzing Merck's aggressive and risky clinical development strategy.

00:18:00 - The Next 10 Years: Will anyone displace Keytruda? Assessing the future strategies of Merck, BMS, AstraZeneca, and Akeso/Summit

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Alex Gray;

LinkedIn: https://www.linkedin.com/in/alexander-gray-934a653/

Keep up with David Radwaner;

LinkedIn: https://www.linkedin.com/in/david-radwaner-1b496343/

Keep up with Tom Brockbank;

LinkedIn: https://www.linkedin.com/in/tom-brockbank-159bb4116/

Follow IDEA Pharma On; Website: https://www.ideapharma.com/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Reagan Jarvis, scientific founder and CEO of Anocca, to explore how TCR-T cell therapy could unlock the next frontier in cancer treatment—particularly for solid tumors.

While CAR-T therapy has transformed outcomes in hematologic cancers, its success has been limited in solid tumors due to a lack of suitable targets. Reagan explains how T-cell receptor (TCR) therapies overcome this challenge by targeting HLA-presented peptide antigens, enabling access to tumor-specific biology that CAR-T cannot reach.

Anocca is building a fully integrated platform that combines: Target mapping of HLA-peptide complexes Rapid generation of optimized T-cell receptors from healthy donors Non-viral gene editing for faster, lower-cost manufacturing End-to-end control from discovery through clinical development.

The conversation also highlights Anocca’s first clinical program targeting mutant KRAS in pancreatic ductal adenocarcinoma, using an umbrella trial design, early intervention strategies, and biomarkers such as circulating tumor DNA (ctDNA). Reagan shares insights on regulatory pathways for individualized therapies, the commercial challenges of patient segmentation, and how software, data, and machine learning are becoming essential to scaling cell therapy platforms.

This episode is a must-listen for anyone interested in cell therapy innovation, cancer immunotherapy, and the future of precision medicine.

Episode Timestamps

00:00 – Introduction to TCR-T and solid tumor challenges

00:48 – Meet Reagan Jarvis and Anocca

02:05 – From New Zealand to Sweden: founder journey

03:08 – Frustration that sparked the platform

04:33 – Why CAR-T struggles in solid tumors

07:24 – The advantage of vertical integration in biotech

09:23 – First non-viral clinical trial challenges

10:56 – Umbrella trials in pancreatic cancer (KRAS focus)

14:13 – Biomarkers and building a target library

17:08 – Software, data, and machine learning in TCR discovery

18:08 – Regulatory pathways for individualized therapies

19:19 – Commercial landscape and target bottlenecks

22:29 – Expanding beyond oncology and partnerships

23:51 – Building a biotech company in Sweden

27:12 – Misconceptions about T-cell biology

30:04 – Milestones and 5-year vision

32:32 – Advice for scientific founders

34:17 – Closing thoughts

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Reagan Jarvis;

LinkedIn: https://www.linkedin.com/in/reagan-jarvis-063984142/

Website: https://www.anocca.com/

Follow IDEA Pharma

Website: https://www.ideapharma.com/

LinkedIn: https://www.linkedin.com/company/idea-pharma/

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of the IDEA Collider, host Mike Rea sits down with Marianne De Backer, CEO of Vir Biotechnology, to explore how she is leading one of biotech’s most complex transformations.

After the rapid rise and decline of COVID-19 revenues tied to sotrovimab, Marianne stepped into Vir Bio in 2023 and led a bold strategic reset—refocusing the company on immuno-oncology, infectious disease, and platform-driven innovation.

The conversation dives into Vir Bio’s next chapter, including its masked T-cell engager (TCE) pipeline and the PRO-XTEN® masking platform, which is designed to overcome the safety challenges of TCEs in the treatment of solid tumors by shielding therapies until they reach the tumor microenvironment.

They also discuss Vir Bio’s advancing hepatitis delta program, currently in registrational Phase 3 trials, and the company’s growing pipeline leveraging the synergy of its AI-driven discovery, protein engineering capabilities, and universal PRO-XTEN® masking technology.

Marianne shares what it takes to lead through a biotech downturn—from restructuring and capital discipline to rebuilding culture, integrating new teams, and positioning for long-term growth.

This episode is a deep dive into biotech turnaround strategy, next-generation cancer therapies, and leadership in times of uncertainty. Episode

Timestamps

00:00 – Introduction and Vir’s transformation story

00:40 – Marianne De Backer’s 30+ year pharma journey

02:42 – Vir’s origins and post-COVID strategic pivot

04:42 – Taking over as CEO during a crisis

06:33 – Lessons from the biotech downturn (“biotech winter”)

08:56 – Astellas partnership and T-cell engager strategy

09:52 – ProXtend platform: masked T-cell engagers explained

13:24 – Clinical data, safety, and tumor targeting

15:32 – Integrating new teams and scientific expertise

17:38 – Expanding the pipeline (HER2, EGFR, oncology)

19:50 – Hepatitis delta program and commercialization plans

22:11 – Funding strategy and biotech market outlook

25:37 – FDA interactions and regulatory perspective

28:13 – AI in drug discovery and clinical trials (Daisy platform)

31:34 – Culture: grit, ingenuity, collaboration, authenticity

34:21 – Personal reflections and leadership mindset

35:46 – Closing thoughts

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Marianne De Backer;

LinkedIn: https://www.linkedin.com/in/marianne-d-de-backer-msc-phd-mba-73403411/

Website: https://www.vir.bio/

Follow IDEA Pharma On;

Website: https://www.ideapharma.com/

LinkedIn: https://www.linkedin.com/company/idea-pharma

Listen to more fantastic podcast episodes: https://ideacollider.simplecast.com/

In this episode of IDEA Collider, host Mike Rea sits down with Nello Mainolfi, founder and CEO of Kymera Therapeutics. Nello shares his journey from medicinal chemist to biotech founder and discusses the opportunities and lessons learned from building a company at the forefront targeted protein degradation.

Episode Timestamps;

00:00 Welcome to Idea Collider

00:18 Kymera 2026 Catalysts

02:33 De Risking with Degraders

02:54 Targeted Protein Degradation 101

06:20 KT-621 STAT6 Degrader

08:16 Rethinking Type 2 Disease Treatment

12:21 Nello’s Path to CEO

16:32 Building a Standalone Biotech

23:19 Partnering with Big Pharma

26:51 Culture and Office Energy

32:03 Capital Plan and Potential Launches

36:24 Belief and Execution Mindset

39:00 Life Outside the Lab

40:07 Where to Follow Kymera

40:35 Closing Thanks

Don't forget to Like, Share, Subscribe, Rate, and Review!

Keep up with Nello Mainolfi & Kymera

LinkedIn: https://www.linkedin.com/in/nello-mainolfi-2b55421a/ or https://www.linkedin.com/company/kymeratherapeutics/

Website: https://www.kymeratx.com/

Follow IDEA Pharma On;

Website: https://www.ideapharma.com/

LinkedIn: https://www.linkedin.com/company/idea-pharma/

Listen to more fantastic podcast episodes: https://podcast.ideapharma.com/